Cookies on this website

We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies.

Continue Find out more

01 Apr 2011
Director/PDMR Shareholding

April 1, 2011 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”) announces that it was notified today that on March 31, 2011 the Ordinary Shares (“Shares”) and American Depository Shares (“ADSs”) in the Company set out below had been awarded under the Executive Annual Incentive Plan (the “Plan”) to the Company’s Executive Directors and Persons Discharging Managerial Responsibility (“PDMRs”). The Shares and ADSs were bought on the market on March 31, 2011 at prices of £18.23 per Share and US$87.5077 per ADS.  The awards are in respect of performance in 2010.

Name of DirectorType of SecurityNo of Ordinary Shares or ADSs purchased
Angus Russel ADSs3,994
Graham Hetherington Shares6,504
Name of PDMR
Michael ColaADSs2,068
Barbara DeptulaADSs1,141
Sylvie GregoireADSs2,139
Tatjana May

Under the terms of the Plan, the awards will not normally be released to participants for three years.  One ADS is equal to three Shares.

In addition, on April 1, 2011 the Company was notified of the release on March 31, 2011 of the Shares and ADSs awarded in 2008 under the Plan. These awards were in respect of performance in 2007. The ADSs below were awarded to Mr Emmens whilst he held the position of Chief Executive Officer of the Company.

In accordance with the rules of the Plan, the following Shares/ADSs were released:

Name of PDMRType of SecurityNo of Shares/ADSs released
Number of Shares/ADSs sold to satisfy tax reliabilities
Matthew EmmensADSs12,8814,345
Angus Russell
Name of PDMR
Michael ColaADSs3,5281,377
Barbara Deptula
Sylvie GregoireADSs790
Tatjana May

Sufficient Shares or ADSs were sold to satisfy tax liabilities as set out above.  Such Shares or ADSs were sold on March 31, 2011, at prices of £18.1818 per Share and $87.1826 per ADS.

This notification is made to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:


Investor Relations  
Eric 781 482 0999


Notes to editors


Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

01 Apr 2011 Director/PDMR Shareholding (34KB PDF)

« Back to Shire news

Did you know...

You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.

Email and SMS alerts

Did you know...

We donated over $35,000 in
outdated laboratory
to local